Of the 12 NSCLC patients selected for immunotherapy (nivolumab), 9/12 (75%) had detectable CTCs of which 6/9 (66.7%) had PD‐L1‐positive CTCs. Here, CD274 is linked to non-small cell lung carcinoma.